The effects of marginal maternal vitamin A status on penta-brominated diphenyl ether mixture-induced alterations in maternal and conceptal vitamin A and fetal development in the Sprague Dawley rat

Birth Defects Res B Dev Reprod Toxicol. 2009 Feb;86(1):48-57. doi: 10.1002/bdrb.20181.

Abstract

Background: Polybrominated diphenyl ether (PBDE) toxicity in rodents can be associated with disruptions in endocrine signaling. We previously reported that the penta-BDE mixture, DE-71, disrupts thyroid hormones and vitamin A metabolism in rats during lactation, and that this disruption is amplified in animals fed diets marginal in vitamin A. The ability of the DE-71 to disrupt vitamin A metabolism during the prenatal period has not been evaluated. While penta-BDE mixtures are not strong teratogens in pregnant animals fed standard commercial laboratory diets, we hypothesized that they could be teratogenic under conditions of marginal vitamin A status.

Methods: rats were fed diets containing 0.4 retinyl equivalents (RE, marginal) or 4.0 RE (adequate) of vitamin A per gram of diet. Pregnant animals were exposed to DE-71 (0, 6, 18, 60, or 120 mg/kg) from gestation days (GD) 6-11.5, or on GD 6-19.5.

Results: DE-71 treatment resulted in dose-responsive reductions in maternal thyroid hormone and markers of vitamin A metabolism, with the latter reduction amplified in marginal vitamin A dams. Fetuses from marginal vitamin A, DE-71-exposed dams exhibited a dose-responsive increase in liver retinol binding protein levels. DE-71 treatment did not result in gross malformations; however, consistent with our hypothesis, GD 20 fetal weights were lower, and skeletal ossification was less when DE-71 exposure occurred concomitant with a marginal vitamin A status. For several endpoints, observable effects were evident at the lowest dose tested, consistent with a dose-response trend.

Conclusions: The results of this study support the concept that marginal vitamin A status enhances the disruptive effects of DE-71 during prenatal development.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abnormalities, Drug-Induced / etiology*
  • Abnormalities, Drug-Induced / pathology
  • Abnormalities, Drug-Induced / prevention & control
  • Administration, Oral
  • Animal Feed
  • Animals
  • Bone Development / drug effects
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Drug Synergism
  • Female
  • Fetal Development / drug effects*
  • Flame Retardants / toxicity*
  • Gene Expression Regulation, Developmental / drug effects
  • Gestational Age
  • Halogenated Diphenyl Ethers / toxicity*
  • Liver / drug effects
  • Liver / embryology
  • Liver / metabolism
  • Maternal Exposure / adverse effects*
  • Pregnancy
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Retinoic Acid / genetics
  • Receptors, Retinoic Acid / metabolism
  • Retinoic Acid Receptor alpha
  • Retinol-Binding Proteins, Cellular / genetics
  • Retinol-Binding Proteins, Cellular / metabolism
  • Thyroid Gland / drug effects
  • Thyroid Gland / metabolism
  • Thyroid Hormones / blood
  • Vitamin A / administration & dosage*
  • Vitamin A / metabolism
  • Vitamin A Deficiency / complications*
  • Vitamin A Deficiency / physiopathology

Substances

  • Flame Retardants
  • Halogenated Diphenyl Ethers
  • Rara protein, mouse
  • Rara protein, rat
  • Rbp1 protein, mouse
  • Receptors, Retinoic Acid
  • Retinoic Acid Receptor alpha
  • Retinol-Binding Proteins, Cellular
  • Thyroid Hormones
  • Vitamin A
  • pentabromodiphenyl ether